- Median overall survival (mOS) was numerically longer for patients receiving ZEJULA regardless of biomarker status, at 46.3 months compared to 43.4 months in the placebo group- No new safety issues were identified SHANGHAI, China and…
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Serhat Gumrukçu, the inventor…
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as…
Issued on: 08/11/2021 - 01:52
Chinese President Xi Jinping, the uncontested leader of the world's most populous nation, heads a pivotal plenary of the ruling party's top figures next…
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker…